---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-026664"
form_type: "8-K/A"
ticker: "CTNM"
cik: "0001855175"
company_name: "Contineum Therapeutics, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:25:20.115039+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Contineum Q2 cash $218.7M; R&D $7.9M; IPO net $107.9M; Phase 2 enrollment on track

## Summary
- Cash, equivalents and marketable securities $218.7M at June 30, 2024, up from $125.2M at YE 2023.
- R&D expenses $7.9M in Q2, down from $9.5M YoY, driven by lower consulting/manufacturing offset by Phase 2 costs.
- G&A expenses $3.0M, up from $1.6M YoY on higher consulting and personnel costs.
- IPO completed in April 2024 with net proceeds of $107.9M.
- Enrollment ongoing in Phase 2 VISTA trial of PIPE-307 for RRMS; expects completion in 2025.

## SEC filing metadata
- accession: 0001437749-24-026664
- form_type: 8-K/A
- ticker: CTNM
- cik: 0001855175
- company_name: Contineum Therapeutics, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 9.01, 2.02, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855175/000143774924026664/0001437749-24-026664-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855175/000143774924026664/cont20240813_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-026664
- JSON: https://secwatch.observer/filing/0001437749-24-026664.json
- Plain text: https://secwatch.observer/filing/0001437749-24-026664.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.